Key result
In lambs with pulmonary hypertension and increased pulmonary blood flow, ET-1 increased pulmonary vascular resistance by 29.7%, whereas it decreased resistance by 24.8% in controls (P<0.05).
Why the study?
How do endothelin-1 and its receptor agonists/antagonists affect pulmonary vascular resistance in a lamb model of pulmonary hypertension with increased pulmonary blood flow?
How do endothelin-1 and its receptor agonists/antagonists affect pulmonary vascular resistance in a lamb model of pulmonary hypertension with increased pulmonary blood flow?
Absolute Event Rate: 29.7% vs -24.8%
p-value: p=<0.05
In a lamb model of congenital heart disease with increased pulmonary blood flow, the pulmonary vascular response to ET-1 shifts from vasodilation to vasoconstriction.
ET-1 vasoconstriction in this lamb model cautions against human extrapolation; leaves open whether endothelin antagonists merit testing in congenital heart disease-associated pulmonary hypertension.
Increased concentrations of endothelin-1 (ET-1) are found in children with congenital heart diseases that produce increased pulmonary blood flow and pulmonary hypertension, but the role of ET-1 in the pathophysiology of pulmonary hypertension is unclear. Therefore, we investigated ET-1-induced vasoactive responses and ET-1 concentrations in an animal model of pulmonary hypertension and increased pulmonary blood flow. Vascular shunts were placed between the ascending aorta and main pulmonary artery in seven late-gestation fetal sheep. Four weeks after spontaneous delivery, ET-1 increased pulmonary vascular resistance by 29.7 +/- 34.4% (P < 0.05), the ETb-receptor agonist [Ala1,3,11,15]ET-1 (4AlaET-1) had no effect, and the ETa-receptor antagonist cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp) (BQ-123) decreased pulmonary vascular resistance by -16.0 +/- 5.6% (P < 0.05). In contrast, in six control lambs with a similar degree of pulmonary hypertension induced by U-46619, ET-1 and 4AlaET-1 decreased pulmonary vascular resistance by 24.8 +/- 17.6, and 20.0 +/- 13.8%, respectively (P < 0.05). In addition, systemic arterial concentrations of immunoreactive ET-1 were elevated in lambs with pulmonary hypertension (29.2 +/- 9.6 vs. 15.2 +/- 10.7 pg/ml, P < 0.05). Pulmonary hypertension and increased pulmonary blood flow alters the response of ET-1 from pulmonary vasodilation to vasoconstriction. These altered responses suggest a role for ET-1 and its receptors in the pathogenesis of pulmonary hypertension secondary to increased pulmonary blood flow.
No takes yet. Share an insight, caveat, or question.
Wong et al. (1995) studied Pulmonary hypertension and increased pulmonary blood flow (n=13). Endothelin-1 (ET-1) vs. Control lambs with U-46619-induced pulmonary hypertension was evaluated on Change in pulmonary vascular resistance (p=<0.05). In lambs with pulmonary hypertension and increased pulmonary blood flow, ET-1 increased pulmonary vascular resistance by 29.7%, whereas it decreased resistance by 24.8% in controls (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: